Connections The partnership will address global food security challenges through optimised agricultural research and data-driven innovation.
2024
connections
Connections EMBL hosted a Science Day with Evonik, bringing together 16 industry experts and EMBL scientists to explore collaborative research opportunities.
2024
connections
EMBL Announcements EMBL and Nikon have formally broadened their partnership to accelerate development of next-generation microscopy technologies.
2024
embl-announcements
Connections EMBL’s first Industry Day offered EMBL scientists a unique opportunity to network with several leading life science companies.
2024
connections
EMBL Announcements Two former EMBL scientists have been recognised for their outstanding contributions to research and leadership capabilities in the fields of evolutionary cell biology and molecular medicine.
2024
alumniembl-announcements
Science & Technology EMBL Hamburg, Johannes Gutenberg University Mainz, Postnova Analytics GmbH, and BioNTech SE have developed a new method to quantitatively investigate sizes of nanoparticles containing mRNA. It may become an important part of regular characterisation of mRNA nanomedicines in the future.
2023
sciencescience-technology
Science & Technology Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
2023
sciencescience-technology
Science & Technology An interdisciplinary collaboration between Hamburg scientists has yielded new insights into the structure and function of a heat-resistant enzyme from an exotic microbe. In this interview, EMBL Hamburg’s Matthias Wilmanns and TUHH’s Garo Antranikian discuss how their collaboration developed and…
2023
sciencescience-technology
EMBLetc Sara Fahs, who did her PhD from EMBL Heidelberg and is one of the newest members of the EMBL alumni association board, writes about key insights from her journey in science and her work on medicinal chemistry, during a career spanning academia and industry.
2023
Science & Technology Pioneers of the mRNA nanomedicines technology receive 2023 Nobel Prize in Physiology or medicine. EMBL is pleased to have supported the development of the application of the mRNA nanomedicine technology through our long-standing collaboration with BioNTech, Johannes Gutenberg University Mainz and…
2023
sciencescience-technology
Lab MattersPeople & Perspectives David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
2023
announcementslab-matterspeople-perspectives
Lab Matters EMBL organised a five-day summer school to help PhD students and postdocs learn more about research and development (R&D) related industry career roles.
2023
eventslab-matters
Science & Technology EMBL researchers use a new cell sorting technology to gain new insights into cellular function in health and disease, as well as for other innovative applications.
2023
sciencescience-technology
EMBL Announcements Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
2023
announcementsembl-announcements
New framework to improve the FAIRness of clinical and molecular datasets
2023
perspectives
Science & Technology HoloFood, the first consistent collection of multiomic data about chicken and salmon gut microbiomes, set to enable the development of better animal feeds.
2023
sciencescience-technologytechnology-and-innovation
ConnectionsLab Matters Vizgen, the life science company dedicated to improving human health by visualising single-cell spatial genomics information, has joined EMBL’s Corporate Partnership Programme.
2023
connectionslab-matters
ConnectionsLab Matters Nikon Europe has intensified its engagement with EMBL's Corporate Partnership Programme to support young scientists.
2023
connectionslab-matters
Connections An annual Corporate Partnership Programme meeting provided a forum for EMBL researchers and industry representatives to discuss mobile labs, planetary biology, and other areas of common interest.
2023
connectionsevents
Connections Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
2022
announcementsconnectionsscience
Science & Technology EMBL researchers, in collaboration with BD Biosciences, have demonstrated a new technology that allows rapid image-based sorting of cells. The new technology represents a major upgrade to flow cytometry and has applications in diverse life science fields.
2022
sciencescience-technology
Science & Technology RNA vaccines, such as the ones for COVID-19, represent a new approach in vaccine technology. Cy Jeffries, faculty staff scientist at EMBL Hamburg, explains the clever technology behind RNA vaccines, and how structural biology contributes to its development. EMBL Hamburg collaborated on several…
2021
sciencescience-technology
Lab MattersScience & Technology Independent impact review finds EMBL experimental services are ‘critical’ for research and endorses EMBL as a world-class service provider for academia and industry.
2021
lab-mattersscience-technology
Science & Technology Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
2021
sciencescience-technology
Lab Matters EMBL’s EU Green Week event showcased various ways molecular biology research can help solve environmental challenges.
2021
lab-matters
Science & Technology Scientists have determined the structure of Glycine Transporter 1. The finding could open new avenues for developing therapeutics for psychiatric disorders
2021
sciencescience-technology
Science & Technology Biotechnology company BioNTech and Johannes Gutenberg University Mainz conduct collaborative research with EMBL scientists at the beamline P12 in Hamburg
2020
sciencescience-technology
Lab Matters The European Molecular Biology Laboratory has secured 6.8 million Euros funding from the European Commission to launch a unique training programme. The ARISE Programme will train and develop Europe’s next generation leadership for research infrastructures in the life sciences.
2020
lab-matters
Lab MattersScience & Technology The new EMBL spinoff company Araxa Biosciences GmbH aims to set new standards for the development of antibody-based therapeutics and diagnostics
2020
lab-mattersscience-technology
EMBL AnnouncementsLab Matters EIPOD4 will prepare researchers for the increasing interdisciplinarity of scientific career paths
2019
embl-announcementslab-matters
Lab Matters Building bonds between academia and industry
2019
lab-matters
ConnectionsLab Matters Joining forces to advance training in biomedical research and therapy
2019
connectionslab-matters
Science & Technology EMBL-EBI industry case study: Biocatalysts
2018
sciencescience-technology
Lab Matters EMBL postdocs discover industry-led research opportunities at the Corporate Summer School
2018
eventslab-matters
ConnectionsLab Matters Pharmaceutical company Sanofi strengthens drug targets discovery collaboration Open Targets
2018
connectionslab-matters
ConnectionsLab Matters EMBL and Promega collaborate to train young scientists
2018
connectionslab-matters
EMBL AnnouncementsLab Matters The ATTRACT initiative, of which EMBL is a partner, has launched an open call for seed funding
2018
embl-announcementslab-matters
ConnectionsLab Matters Roche and EMBL join forces
2018
connectionslab-matters
Lab MattersPeople & Perspectives EMBL-EBI PhD student launches start-up focusing on epigenetics and wellbeing
2018
lab-matterspeople-perspectives
ConnectionsLab Matters New partner strengthens drug discovery collaboration
2018
connectionslab-matters
Lab MattersScience & Technology New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies
2018
lab-mattersscience-technology
ConnectionsLab Matters Joining forces for single-cell research
2018
connectionslab-matters
Lab MattersPeople & Perspectives Takeda joins pioneering public-private drug discover collaboration Open Targets
2017
lab-matterspeople-perspectives
Lab MattersPeople & Perspectives EMBL and HeidelbergCement sign Memorandum of Understanding
2017
lab-matterspeople-perspectives
Science & Technology Exploring the potential of user experience for life sciences through industry workshops
2017
eventsscience-technology
ConnectionsLab Matters Accelerating researchers’ access to next-generation light-sheet microscopy
2017
connectionslab-matters
People & Perspectives EMBL alumnus Joep Muijrers talks about making the transition from science into business
2017
alumnipeople-perspectives
Science & Technology Side-effects of leukaemia drug explained, reveal possibility of repurposing to treat other diseases
2016
sciencescience-technology
Connections Alumnus and entrepreneur Marc Zabeau speaks at inaugural Life Science Funders and Foundations event
2016
connectionsevents
Connections Abel Ureta-Vidal and Louise Modis join colleagues and peers at gathering of UK-based alumni
2016
alumniconnections
ConnectionsLab Matters Pioneering target validation collaboration expands to accelerate drug discovery research.
2016
connectionslab-matters
Science & Technology Protein screens developed at EMBL Hamburg now commercially available
2016
sciencescience-technology
ConnectionsLab Matters Identifying evidence-based relationships between drug targets and diseases.
2015
connectionslab-matters
EMBL AnnouncementsLab Matters EI3POD: flagship interdisciplinary postdoc programme opens its doors to academia and industry.
2015
embl-announcementslab-matters
Connections Industrial partners and BioStruct-X facility members gather for Workshop at EMBL Hamburg.
2015
connectionsevents
Lab Matters Career insights from Riccardo Cortese, whose start-up is developing an Ebola vaccine candidate.
2015
alumnilab-matters
Lab Matters Alumni in senior positions in industry share career challenges, highlights and EMBL’s continuing role.
2015
alumnilab-matters
EMBL’s corporate partners zoom in on big data and bioimaging.
2015
events
Life Science Nord event reveals how pharmaceutical companies use synchrotrons for their research.
2014
events
Lab Matters As the Lab turns 40, staff and alumni share 40 things that make EMBL, EMBL
2014
lab-matters
Lab Matters Two EMBL alumni, each developing community-led tools to support life science research
2014
alumnilab-matters
ConnectionsLab Matters A new EMBL-EBI biomedical initiative works to determine the best target proteins for new drugs.
2014
connectionslab-matters
Lab Matters The European Commission has awarded 3.7 Million Euro under the European Union Framework 6 Programme over the next four years to a new Marie Curie Research Training Network, coordinated by Dr. Andreas Ladurner at the European Molecular Biology Laboratory (EMBL). The long molecules of DNA that carry…
2007
lab-matters
Lab MattersScience & Technology Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new…
2006
lab-mattersscience-technology
No matching posts found
Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.
EMBLetc. archive
